Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: A cohort study

Arthritis Research and Therapy

Volumn 12, Issue 1, 2010, Pages

  Ursum, Jennie ^a   Bos, Wouter H ^a   van Dillen, Nancy ^a   Dijkmans, Ben A C ^a,b   van Schaardenburg, Dirkjan ^a,b  

^a JAN VAN BREEMEN INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICITRULLINATED PROTEIN ANTIBODY; AUTOANTIBODY; IMMUNOGLOBULIN M RHEUMATOID FACTOR; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ARTHRITIS; ARTICLE; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RADIOGRAPHY;

EID: 79651473974     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2907     Document Type: Article

References (32)

1. Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R949-R958. doi:10.1186/ar1767, 10.1186/ar1767, 1257421, 16207336.
2. Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005, 64:1744-1749. 10.1136/ard.2004.033571, 1755292, 15843452.
3. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003, 62:120-126. 10.1136/ard.62.2.120, 1754441, 12525380.
4. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004, 63:1090-1095. 10.1136/ard.2003.014233, 1755129, 15308518.
5. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004, 63:1085-1089. 10.1136/ard.2003.016808, 1755123, 15308517.
6. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005, 64:196-201. 10.1136/ard.2003.019992, 1755350, 15458956.
7. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, Rantapaa-Dahlqvist S. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006, 65:453-458. 10.1136/ard.2005.041376, 1798112, 16176994.
8. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, Uffmann M, Smolen JS. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007, 46:342-349. 10.1093/rheumatology/kel237, 16899498.
9. Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, van der Horst-Bruinsma IE, Tak PP, van de Stadt R, van der Laken CJ, Dijkmans BA, van Schaardenburg D. Arthritis development in arthralgia patients is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 2009,
10. Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 2007, 26:201-204. 10.1007/s10067-006-0275-5, 16572283.
11. Del Val Del Amo N, Ibanez BR, Fito MC, Gutierrez PR, Loza CE. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 2006, 24:281-286.
12. Jansen LM, van Schaardenburg D, van D, Stadt RJ, de Koning MH, Dijkmans BA. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 2003, 30:1691-1695.
13. Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, Maher NE, Parker A, Roubenoff R, Izmailova E, Coblyn JS, Weinblatt ME, Shadick NA. Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis 2008, 67:358-363. 10.1136/ard.2007.071662, 17666451.
14. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, Hoogen FH, van't Hof M, Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000, 43:1831-1835. 10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6, 10943873.
15. Shovman O, Gilburd B, Zandman-Goddard G, Sherer Y, Orbach H, Gerli R, Shoenfeld Y. The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis. Clin Dev Immunol 2005, 12:197-202. 10.1080/17402520500233510, 2275423, 16295525.
16. De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, Lebeer K, Wyns B, Vincent C, Mielants H, Boullart L, Serre G, Veys EM, De Keyser F. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004, 63:1587-1593. 10.1136/ard.2003.017574, 1754859, 15547083.
17. Lee DM, Phillips R, Hagan EM, Chibnik LB, Costenbader KH MM, Schur PH. Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis. Ann Rheum Dis 2009, 68:201-208. doi:10.1136/ard.2007.084509 [Published Online First: 7 April 2008, 10.1136/ard.2007.084509, 18390910.
18. Meyer O, Nicaise-Roland P, Santos MD, Labarre C, Dougados M, Goupille P, Cantagrel A, Sibilia J, Combe B. Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther 2006, 8:R40. doi:10.1186/ar1896, 10.1186/ar1896, 1526612, 16469118.
19. Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P, van Der HD, Landewe R, Kvien TK. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008, 67:212-217. 10.1136/ard.2006.068247, 17526555.
20. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, Ruzickova S. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003, 62:427-430. 10.1136/ard.62.5.427, 1754544, 12695154.
21. Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol 2004, 16:246-253. 10.1097/00002281-200405000-00013, 15103252.
22. van Schaardenburg D, Lagaay AM, Otten HG, Breedveld FC. The relation between class-specific serum rheumatoid factors and age in the general population. Br J Rheumatol 1993, 32:546-549. 10.1093/rheumatology/32.7.546, 8339123.
23. del Puente A, Knowler WC, Pettitt DJ, Bennett PH. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum 1988, 31:1239-1244. 10.1002/art.1780311004, 3178905.
24. Paimela L, Palosuo T, Leirisalo-Repo M, Helve T, Aho K. Prognostic value of quantitative measurement of rheumatoid factor in early rheumatoid arthritis. Br J Rheumatol 1995, 34:1146-1150. 10.1093/rheumatology/34.12.1146, 8608356.
25. van Leeuwen MA, Westra J, van Riel PL, Limburg PC, van Rijswijk MH. IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression?. Scand J Rheumatol 1995, 24:146-153. 10.3109/03009749509099303, 7777825.
26. Nielen MM, Horst AR, van Schaardenburg D, Horst-Bruinsma IE, Stadt RJ, Aarden L, Dijkmans BA, Hamann D. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005, 64:1199-1204. 10.1136/ard.2004.029389, 1755615, 15640269.
27. Nielen MM, van Schaardenburg D, Reesink HW, Stadt RJ, Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50:380-386. 10.1002/art.20018, 14872479.
28. Fransen J, van Riel PL. DAS remission cut points. Clin Exp Rheumatol 2006, 24:S29-S32.
29. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145. 10.1002/art.1780230202, 7362664.
30. Nell-Duxneuner V, Machold K, Stamm T, Eberl G, Heinzl H, Hoefler E, Smolen JS, Steiner G. Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study. Ann Rheum Dis 2009, 69:169-174.
31. Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, Stadt RJ, van Schaardenburg D, Dijkmans BA, Nurmohamed MT. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 2008, 35:1972-1977.
32. Ursum J, Bos WH, Stadt RJ, Dijkmans BA, van Schaardenburg D. Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems. Arthritis Res Ther 2009, 11:R75. 10.1186/ar2704, 2714121, 19460147.